Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of [14C]SIM0270 in Healthy Chinese Men
NCT06654791Phase 1Active, not recruiting
- Sponsor
- Simcere Pharmaceutical Group
- Start
- Oct 2024
- Primary completion
- Mar 2025
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SIM0270 in breast cancer, sponsored by Simcere Pharmaceutical Group. Primary endpoints: Mean Cumulative Amount of Total Radioactivity (CumAe) of [14C]SIM0270 Excreted in Urine, Feces, and Total, Mean Cumulative Amount of Total Radioactivity Expressed as a Percentage of the Radioactive Dose Administered (CumFe) and 4 more. Started Oct 2024; status: active, not recruiting.
02
Drugs
SIM0270
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06654791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06654791.